SCHEMBL20021956

SCHEMBL20021956

COC(=O)c1cnc(OC2CCCC2)c(-c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.53
PDGFRB P09619 1/20 0.47
KDR P35968 1/20 0.47
NEK1 Q96PY6 1/20 0.42
SGK1 O00141 1/20 0.42
CAMKK2 Q96RR4 1/20 0.42
EGFR P00533 1/20 0.42
TACR2 P21452 1/20 0.42
GABRA5 P31644 1/20 0.41
CTSA P10619 1/20 0.41
DHODH Q02127 1/20 0.41
CNR2 P34972 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL925225 0.89 CNR1 (0.53) CNR1NEK1TACR2CNR2PDE4A
SCHEMBL20021958 0.88 CNR1 (0.54) CNR1DHODHCNR2PDE4APDE4B
SCHEMBL924433 0.85 CNR1 (0.44) CNR1PDGFRBKDRGABRA5CNR2
SCHEMBL20021946 0.79 PDE4D (0.54) EGFRPDE4APDE4BPDE4CPDE4D
SCHEMBL924247 0.79 KMT2A (0.47) CNR1GABRA5PDE4APDE4BPDE4C
SCHEMBL20021961 0.77 CNR1 (0.54) CNR1CNR2PDE4APDE4BPDE4C
SCHEMBL71189 0.76 PDE4D (0.46) PDE4APDE4BPDE4CPDE4D
SCHEMBL2704505 0.76 CNR1 (0.71) CNR1PDGFRBKDRCNR2SCN5A
SCHEMBL11709594 0.75 PDGFRB (0.56) PDGFRBKDRNEK1SGK1CAMKK2
SCHEMBL15670125 0.75 CNR1 (0.48) CNR1PDGFRBKDRNEK1SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092866-A1 SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS BCL9, BCL9L, BCL3 CNR1 1005/4885PDGFRB 765/4885KDR 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.